Given the nature of the medicinal products concerned, and the probability that the conditions to be treated are rare, it is not appropriate to lay down overly prescriptive requirements to establish that the criteria are met.
Recital 4, Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…
In forcesince 27 Apr 2000cited 1×
Judgment of the General Court (Second Chamber) of 5 December 2018. Bristol-Myers Squibb Pharma EEIG v European Commission and European MedicDecision
In the third place, the applicant submits that the COMP should have accepted the possibility of finding significant benefit on the basis of best estimates or even assumptions rather than insisting on conclusive evidence. In that regard, …
5 Dec 2018 · 62016TJ0329